Status Approved
First Submitted Date
2017/07/13
Registered Date
2017/09/22
Last Updated Date
2017/08/25
CRIS Required
WHO ICTRP (International Clinical Trial Registry Platform) Required
1. Background
CRIS Registration Number |
KCT0002477 |
---|---|
Unique Protocol ID | 2017-04-006 |
Public/Brief Title | Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects. |
Scientific Title | A Randomized, Open-label, 2-Way, 2-Period, Single-Dose Crossover Clinical Study to Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix Tablet 1 mg and Champix® Tablet 1 mg in Healthy Adult Male Subjects |
Acronym | JLP-1607-101-PK |
MFDS Regulated Study | Yes |
IND/IDE Protocol | Yes |
Registered at Other Registry | No |
Healthcare Benefit Approval Status |
2. Institutional Review Board / Ethics Committee
Board Approval Status | Submitted approval |
---|---|
Board Approval Number | INHAUH 2017-04-006-001 |
Approval Date | 2017-05-22 |
Institutional Review Board Name | Inha Univ Hospital IRB |
Institutional Review Board Address | |
Institutional Review Board Telephone | |
Data Monitoring Committee | No |
3. Contact Details
Contact Person for Principal Investigator / Scientific Queries | |
---|---|
Name | sangheon Cho |
Title | associate professor |
Telephone | +82-32-890-1122 |
Affiliation | Inha University Hospital |
Address | 27, Inhang-ro, Jung-gu, Incheon, Korea |
Contact Person for Public Queries | |
Name | sangheon Cho |
Title | associate professor |
Telephone | +82-32-890-1122 |
Affiliation | Inha University Hospital |
Address | 27, Inhang-ro, Jung-gu, Incheon, Korea |
Contact Person for Updating Information | |
Name | Jongwoo Kim |
Title | CRA |
Telephone | +82-2-549-7451 |
Affiliation | Jeil Pharmaceutical |
Address | 343, Sapyeong-daero, Seocho-gu, Seoul |
4. Status
Study Site | Single | |
---|---|---|
Overall Recruitment Status | Active, not recruiting | |
Date of First Enrollment | 2017-07-06 Actual | |
Target Number of Participant | 30 | |
Primary Completion Date | 2017-07-26 , Actual | |
Study Completion Date | 2017-12-31 , Anticipated | |
Recruitment Status by Participating Study Site 1 | ||
Name of Study | Inha University Hospital | |
Recruitment Status | Active, not recruiting | |
Date of First Enrollment | 2017-07-06 , |
5. Source of Monetary / Material Support
1. Source of Monetary/Material Support | |
---|---|
Organization Name | Jeil Pharmaceutical |
Organization Type | Pharmaceutical Company |
Project ID | JLP-1607-101-PK |
6. Sponsor Organization
1. Sponsor Organization | |
---|---|
Organization Name | Jeil Pharmaceutical |
Organization Type | Pharmaceutical Company |
7. Study Summary
Lay Summary | This study is a randomized, open-label, 2-way, 2-period, single-dose crossover clinical study to compare the pharmacokinetic characteristics and the safety between zeropix tablet 1 mg and champix® tablet 1 mg in healthy adult male subjects |
---|
8. Study Design
Study Type | Interventional Study |
---|---|
Study Purpose | Others (Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects) |
Phase | Phase1 |
Intervention Model | Cross-over |
Blinding/Masking | Open |
Allocation | RCT |
Intervention Type | Drug |
Intervention Description | Single-Dose Crossover Clinical Study to Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix Tablet 1 mg and Champix® Tablet 1 mg in Healthy Adult Male Subjects |
Number of Arms | 2 |
Arm 1 |
Arm Label A |
Target Number of Participant 15 |
|
Arm Type Others |
|
Arm Description Period 1: Zeropix 1mg single dosing Period 2: Champix 1mg single dosing |
|
Arm 2 |
Arm Label B |
Target Number of Participant 15 |
|
Arm Type Others |
|
Arm Description Period 1: Champix 1mg single dosing Period 2: Zeropix 1mg single dosing |
9. Subject Eligibility
Condition(s)/Problem(s) |
* (Z00-Z99)Factors influencing health status and contact with health services (Z72.0)Problems related to tobacco use |
---|---|
Rare Disease | No |
Inclusion Criteria |
Gender Male |
Age 19Year~45Year |
|
Description 1) Healthy male older than 19 to 45 years at the time of screening 2) Body weight more than 50kg and Body Mass Index(BMI) 18~29 kg/m2 ☞ BMI = (weight [kg])/(height [m])2 3. Subject judged to be eligible by physical examination and interview conducted according to the study protocol. Thus, Subject should not have congenital/chronic disease or pathological symptoms/findings 4. Subject judged to be eligible by clinical tests such as hematology test, blood chemistry test, serum electrolyte test, urine test, Urine Microscopy urine test, serology test performed according to the study protocol 5. Subject who fully understands the clinical trials after in-depth explanation, volunteers to join the clinical trials and signs inform consent |
|
Exclusion Criteria |
1) Subject currently with or has a history of cardiovascular , respiratory, hepatic, renal, neurological, endocrine, hemato-oncology, psychiatric, urinary diseases that is clinically significant 2) Subject with a history of significant hypersensitivity or clinically significant hypersensitivity reaction to varenicline and other drugs (aspirin, antibiotic…etc.) 3) Systolic blood pressure ⩽100mmHg or ⩾ 150mmHg, diastolic blood pressure⩽55mmHg or ⩾ 95mmHg 4) Subject with a history of gastrointestinal disease (i.e. Crohn’s disease, ulcer…etc.) or gastrointestinal surgery (not including, simple appendectomy or hernia surgery) that can affect drug absorption 5) Subject with the following results in the clinical laboratory tests - Aspartate Transaminase(AST) or Alanine Transaminase(ALT) > 2 x upper limit of normal range - Total Bilirubin > 2.0 mg/dl - CK > 2 x upper limit of normal range - eGFR < 60 mL/min/1.73m2 6) Subject who takes alcohol > 21 units/week, 1unit=10g=12.5ml of pure alcohol) or can’t stop drinking during the clinical trials 7) Subject who smokes> 10 cigarettes/day or can’t stop smoking during the clinical trials 8) Taking medication involved in other clinical trials within 90 days before the first administration 9) Whole blood donation within 60 days or component blood donation within 30 days before the first administration 10) Taking metabolizing enzyme inducers or inhibitors such as barbitals within 30 days before the first administration 11) Taking Prescription drug (ETC) or oriental medicine within two weeks and any OTC within 2 weeks before the first administration 12) Subject with mental illness or substance abuse 13) Genetic muscle disease, or family history, or history of drug-induced rheumatoid arthritis. 14) Consumption of food which can significantly change the absorption, distribution, metabolism and excretion of a drug within 7 days before the first administration (such as grapefruit or its components) 15) Those who do not agree with the approved method of contraception during the clinical trial 16) Patients judged as inadequate and clinical trials to test self-determined target for any reason. |
Healthy Volunteers | Yes |
10. Outcome Measure(s)
Type of Primary Outcome | Pharmacokinetics | |
---|---|---|
Primary Outcome(s) 1 | ||
Outcome | Varenicline AUCt, Cmax |
|
Timepoint | 0h (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96h |
|
Secondary Outcome(s) 1 | ||
Outcome | Varenicline tmax |
|
Timepoint | 0h (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96h |
|
Secondary Outcome(s) 2 | ||
Outcome | Varenicline t1/2 |
|
Timepoint | 0h (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96h |
|
Secondary Outcome(s) 3 | ||
Outcome | Varenicline AUC∞ |
|
Timepoint | 0h (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96h |
11. Study Results and Publication
Result Registered |
---|
12. Sharing of Study Data(Deidentified Individual-Patient Data, IPD)
Sharing Statement | No |
---|
TOP
BOTTOM
화면 최하단으로 이동